Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 15/20 | 0.54 |
| ▸ | CCNH | P51946 | 15/20 | 0.54 |
| ▸ | MNAT1 | P51948 | 13/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.54 |
| ▸ | CDK2 | P24941 | 12/20 | 0.54 |
| ▸ | CCNK | O75909 | 12/20 | 0.54 |
| ▸ | CDK12 | Q9NYV4 | 12/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.54 |
| ▸ | CDK9 | P50750 | 11/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993829 | 1.00 | CDK7 (0.54) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL21026876 | 0.84 | CDK5 (0.69) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL24839369 | 0.84 | CDK7 (0.55) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL30957595 | 0.84 | CCNK (0.48) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL24900503 | 0.84 | CCNK (0.48) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL24900493 | 0.84 | TDO2 (0.47) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL30957590 | 0.84 | TDO2 (0.47) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL21629046 | 0.83 | CCNK (0.44) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL21178668 | 0.83 | CLK1 (0.50) | CDK7CCNHMNAT1CCNE1CDK2 | |
| SCHEMBL21184587 | 0.83 | CCNK (0.42) | CDK7CCNHMNAT1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4370212-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024084394-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023143482-A1 | 2-AMINOPYRIMIDINE COMPOUND OR SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023116761-A1 | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 英矽智能科技知识产权有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2015154038-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | CDK7 79/4885CCNH 917/4885MNAT1 397/4885 |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 33/4885MNAT1 92/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 33/4885MNAT1 92/4885 |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | CDK7 97/4885CCNH 546/4885MNAT1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.